HOME >> BIOLOGY >> NEWS
After 2 years, study shows Revlimid patients live longer and remain transfusion free

Orlando, FL (December 11, 2006) -- Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) at this years American Society of Hematology (ASH) meeting. This breakthrough data showed that in MDS patients with chromosome 5q deletion treatment with Revlimid can provide long-term durable results and help them to achieve blood transfusion independence and remain transfusion free.

"These landmark data demonstrate that Revlimid, in many cases, eliminates all signs of the cancers genetic cause, on partial deletion of chromosome 5, and as a consequence reduce or even eliminate the need for transfusions in many patients with MDS. After over two years of follow up, these responses have sustained," said List, Professor of Oncology and Medicine and Chief, Division of Hematology Malignancies at Moffitt, and lead investigator of the study. "It is very rewarding to see patients treated with Revlimid, living longer, living three or four years transfusion free and having a better quality of life overall."

MDS, a cancer in which the bone marrow fails to make enough functioning blood cells, affects 300,000 people worldwide killing 60,000 to 70,000 a year. MDS patients suffer from anemia and fatigue and need whole-body blood transfusions as much as twice a month. Repeated transfusions can lead to a toxic buildup called "iron overload" that severely damages the heart, liver and pancreas, and patients eventually succumb to the disease.

The data presented by List showed that two-thirds of patients who received Revlimid were completely freed from the need for blood transfusions. More significantly, in 44 percent of patients, there was no detectable trace of the cancer and after two years of follow-up the median duration has not yet been achieved.

Additional data o
'"/>


11-Dec-2006


Page: 1 2

Related biology news :

1. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
2. After scrutiny, preemie lung treatments turn out to be safe, effective
3. After North Korea test, what can be done to reduce the growing nuclear threat?
4. After insects attack, plants bunker sugars for later regrowth
5. After the Hurricanes
6. After the yeast is gone bacteria continue to develop flavor of sparkling wine
7. After a time-shift, mixed signals from the circadian clock
8. After flu exposure, mild exercise protects mature mice from dying
9. Allergy battle could be won in five years, says scientist
10. New study warns limited carbon market puts 20 percent of tropical forest at risk
11. Clones on task serve greater good, evolutionary study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics ... recognition and multiple awards for not only the products and treatments developed, but ... and Vivace® Microneedle RF. All the brands built by ABM have received several ...
(Date:6/28/2020)... ... June 25, 2020 , ... Genedata, ... that it has entered into a multi-year contract with Merus N.V., a ... translational and clinical research strategy to discover and develop ground-breaking drugs. The ...
(Date:6/23/2020)... ... ... The field of quantitation of large molecules or proteins has been around for a ... of mass spectrometry in this field has gained a lot of momentum in the ... approach to use (LBA or MS)?” In many cases, either technology can answer ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... Modality ... for free its new white paper – Simulated Transport Methodologies. Regulatory expectations ... biologics licensing application (BLA). In response, Modality Solutions shares an explanation of ...
(Date:8/3/2020)... ... August 03, 2020 , ... ERT, ... President and CEO has been named one of the 100 most inspiring individuals ... PharmaVoice 100 honorees are selected based on how they have inspired their colleagues ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON ... of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes ... globe, requiring fast track capacity to provide patients with urgently needed vaccines and ...
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
Breaking Biology Technology:
Cached News: